Hosted on MSN10mon
Improving cancer immunotherapy by prolonging T-cell survivalThe study showed that T-cells expressing the cell receptor CD38 were more susceptible to exhaustion. Using an anti-CD38 antibody, the research team was able to block CD38 and overcome T-cell ...
Medpage Today on MSN4mon
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsSubsequently, CAR T-cell therapies for multiple myeloma received FDA approval. Currently available agents target CD38, ...
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...
Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...
The therapy works by reprogramming a patient's T-cells with a transgene encoding a ... a PI and an anti-CD38 monoclonal antibody. Initially, the FDA's decision was expected to arrive by the ...
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
Investing.com -- Genmab (CSE: GMAB) (NASDAQ: GMAB) announced on Monday, March 10, that Johnson & Johnson (NYSE: JNJ) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback